Zosano Pharma Corporation (ZSAN) Stock Price, Quote, News and Overview
NASDAQ:ZSAN - Nasdaq - US98979H3012 - Common Stock
ZSAN Quote, Performance and Key Statistics
0.5576
+0.04 (+7.23%)
The current stock price of ZSAN is 0.5576 null. In the past month the price decreased by -67.77%. In the past year, price decreased by -98.31%.
ZSAN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About ZSAN
Company Profile
Zosano Pharma Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Fremont, California and currently employs 40 full-time employees. The company went IPO on 2015-01-27. Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The firm is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its transdermal microneedle system (the System). Its System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic (PK) profile compared to original dosage forms. The System consists of a three cm square to six cm square array of titanium microneedles approximately 200-350 microns in length, coated with a hydrophilic formulation of drug, mounted on an adhesive patch. The company is focused on development of its lead product candidate, M207, a formulation of zolmitriptan, which is used as an acute treatment for migraine. Its zolmitriptan formulation is delivered utilizing its system. M207 is designed to provide rapid absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract.
Company Info
Zosano Pharma Corporation
34790 Ardentech Ct
Fremont CALIFORNIA 94555 US
CEO: Steven Lo
Employees: 40
Company Website: http://www.zosanopharma.com/
Phone: 15107451200.0
Zosano Pharma Corporation / ZSAN FAQ
What is the stock price of Zosano Pharma Corporation today?
The current stock price of ZSAN is 0.5576 null. The price increased by 7.23% in the last trading session.
What is the ticker symbol for Zosano Pharma Corporation stock?
The exchange symbol of Zosano Pharma Corporation is ZSAN and it is listed on the Nasdaq exchange.
On which exchange is ZSAN stock listed?
ZSAN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Zosano Pharma Corporation stock?
7 analysts have analysed ZSAN and the average price target is 21.42 null. This implies a price increase of 3741.46% is expected in the next year compared to the current price of 0.5576. Check the Zosano Pharma Corporation stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Zosano Pharma Corporation worth?
Zosano Pharma Corporation (ZSAN) has a market capitalization of 2.73M null. This makes ZSAN a Nano Cap stock.
How many employees does Zosano Pharma Corporation have?
Zosano Pharma Corporation (ZSAN) currently has 40 employees.
Is Zosano Pharma Corporation (ZSAN) expected to grow?
The Revenue of Zosano Pharma Corporation (ZSAN) is expected to decline by -90.9% in the next year. Check the estimates tab for more information on the ZSAN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Zosano Pharma Corporation (ZSAN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZSAN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZSAN, evaluating the profitability, health, valuation and growth aspects
- Zosano Pharma Corporation (ZSAN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Zosano Pharma Corporation (ZSAN) Sales and EPS estimates to see what analysts future expectations are.
- Zosano Pharma Corporation (ZSAN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Zosano Pharma Corporation (ZSAN) Insider and Institutional Ownership to learn about the owners and their transactions.
- Zosano Pharma Corporation (ZSAN) Stock Chart to make your own analysis
- Zosano Pharma Corporation (ZSAN) Latest news and press-releases to stay up to date.
Does Zosano Pharma Corporation (ZSAN) stock pay dividends?
ZSAN does not pay a dividend.
When does Zosano Pharma Corporation (ZSAN) report earnings?
Zosano Pharma Corporation (ZSAN) will report earnings on 2022-08-08.
What is the Price/Earnings (PE) ratio of Zosano Pharma Corporation (ZSAN)?
Zosano Pharma Corporation (ZSAN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.41).
ZSAN Technical Analysis
ZSAN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZSAN. Both the profitability and financial health of ZSAN have multiple concerns.
ZSAN Financial Highlights
Over the last trailing twelve months ZSAN reported a non-GAAP Earnings per Share(EPS) of -8.41. The EPS decreased by -1951.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -8362.12% | ||
| ROA | -208.66% | ||
| ROE | 41.36% | ||
| Debt/Equity | 0 |
ZSAN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to ZSAN. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 98.64% and a revenue growth -90.9% for ZSAN